Congress extends Hatch-Waxman exclusivity to "old" antibiotics
This article was originally published in Scrip
Executive Summary
Antibiotic incentive legislation passed by the US House and Senate is expected to spur research and development of older antibiotics for new uses. It could also result in the approval of new chemical entities that were the subject of previously submitted, but never approved, applications to theFDA.